Senores Pharmaceuticals IPO
Historical offer record. This offer is closed for applications. Prices and subscriptions describe the past offer; GMP observations are unofficial past records, not current quotes or listing predictions.
Data provider: FinAPI. This is a third-party summary, not an official prospectus. Read our data limitations and editorial policy.
No GMP observations are available for this historical offer record. No premium or listing-gain estimate is shown.
Price band
₹372 – ₹391
Lot size
38 shares
Offer application amount
₹14,858
Issue size
₹582.11 Cr
Historical offer amount for 1 lot at the upper issue price. Confirm the lot size and application terms in the issuer prospectus.
Reported IPO schedule
| Open date | 20 Dec 2024 |
| Close date | 24 Dec 2024 |
| Allotment finalisation | 26 Dec 2024 |
| Refund initiation | 27 Dec 2024 |
| Shares credited to demat | 27 Dec 2024 |
| Reported listing date | 30 Dec 2024 |
Issue size
About Senores Pharmaceuticals
Senores is one of the great pharmaceuticals focusing on generic medicine. It has also been certified by global food and drug authorities. Nowadays it is committed to providing good quality and manufacturing products to raise new demand in the global healthcare industry. At present, they have a goal of innovation, production, and manufacturing verticals and also have the vision to make more affordable and accessible healthcare, especially for varied types of products. Moreover, they are providing a dynamic strategy, offering them access to products that are good to go. Noticeably, they have the strength of identifying, producing, specialty, underpenetrated, and complex pharmaceutical products, and received the reliability of customers to choose them over and over. It is focused on the US and Canadian markets, simultaneously 43 countries have also felt the presence of them. The company also manufactures critical care injectables and active pharmaceutical ingredients (APIs).
Company summary supplied by FinAPI. Read the prospectus for the issuer's disclosures and audited financials.
Offer documents and primary references
Read the issuer's offer document and any corrigenda for the full disclosures. A third-party details page is a summary; SEBI filing access does not imply an endorsement of the offer or this website.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.